Online inquiry

IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12974MR)

This product GTTS-WQ12974MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12974MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6773MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ3903MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ13093MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ10073MR IVTScrip™ mRNA-Anti-FN, L19TNF(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA L19TNF
GTTS-WQ2566MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ5404MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ4961MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ11345MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-551
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW